Hoffmann J C, Bahr M J, Tietge U J, Braunstein J, Bayer B, Böker K H, Manns M P
Division of Rheumatology, Medizinische Hochschule Hannover, Germany.
J Hepatol. 1996 Oct;25(4):465-73. doi: 10.1016/s0168-8278(96)80205-4.
BACKGROUND/AIMS: Multiple immune functions, such as cytotoxic reactions, B cell differentiation, and monocyte activation, are mediated via the adhesion receptor/ligand pairs CD2/lymphocyte function-associated antigen(LFA)-3 and LFA-1/ intercellular adhesion molecule(ICAM)-1. Since soluble forms of LFA-3 (sLFA-3) and ICAM-1 (sICAM-1) can interfere with these functions, we asked whether increased levels of sLFA-3 can be found in patients with different forms of chronic liver disease and/or hepatocellular carcinoma.
sLFA-3 was measured in sera from 84 patients with chronic liver disease (39 with chronic viral liver disease, 30 with autoimmune liver disease, 12 with alcoholic cirrhosis, 3 with other causes of cirrhosis), 24 patients with hepatocellular carcinoma (15 with and 9 without cirrhosis), and 61 normal controls. From 36 of the patients with liver cirrhosis, arterial and hepatic venous serum samples were simultaneously obtained and tested for sLFA-3 and sICAM-1.
In comparison to controls, sLFA-3 levels were elevated in patients with liver cirrhosis due to autoimmune liver disease (p < 0.0001) and viral liver disease (p = 0.001), but not in patients with alcoholic cirrhosis. Increased sLFA-3 levels were also found in patients with hepatocellular carcinoma and liver cirrhosis. However, sLFA-3 was not significantly elevated in sera from patients with autoimmune liver disease, viral liver disease, and hepatocellular carcinoma without concomitant liver cirrhosis. No difference was found between arterial and hepatic venous serum levels of sLFA-3 and sICAM-1. sLFA-3 levels correlated positively with aspartate transaminase, alkaline phosphatase, bilirubin, sICAM-1, and inversely with albumin and cholinesterase.
Taken together, sLFA-3 serum concentrations of patients with liver cirrhosis due to autoimmune liver disease or viral liver disease and of patients with hepatocellular carcinoma and cirrhosis are significantly increased compared to controls. Elevated sLFA-3 and sICAM-1 levels might reflect the generalized inflammation in cirrhosis and by interference with cell-cell interactions sICAM-1 and sLFA-3 may limit the extent of inflammation.
背景/目的：多种免疫功能，如细胞毒性反应、B细胞分化及单核细胞激活，是通过黏附受体/配体对CD2/淋巴细胞功能相关抗原（LFA）-3和LFA-1/细胞间黏附分子（ICAM）-1介导的。由于可溶性形式的LFA-3（sLFA-3）和ICAM-1（sICAM-1）可干扰这些功能，我们探究不同形式的慢性肝病和/或肝细胞癌患者血清中sLFA-3水平是否升高。
检测了84例慢性肝病患者（39例慢性病毒性肝病、30例自身免疫性肝病、12例酒精性肝硬化、3例其他原因所致肝硬化）、24例肝细胞癌患者（15例伴有肝硬化，9例不伴有肝硬化）及61例正常对照者血清中的sLFA-3。从36例肝硬化患者中同时采集动脉血和肝静脉血样本，检测sLFA-3和sICAM-1。
与对照组相比，自身免疫性肝病所致肝硬化患者（p < 0.0001）及病毒性肝病患者（p = 0.001）血清中sLFA-3水平升高，而酒精性肝硬化患者未升高。肝细胞癌患者及伴有肝硬化患者血清中sLFA-3水平也升高。然而，不伴有肝硬化的自身免疫性肝病、病毒性肝病及肝细胞癌患者血清中sLFA-3未显著升高。动脉血和肝静脉血中sLFA-3和sICAM-1水平无差异。sLFA-3水平与天冬氨酸转氨酶、碱性磷酸酶、胆红素、sICAM-1呈正相关，与白蛋白和胆碱酯酶呈负相关。
总体而言，与对照组相比，自身免疫性肝病或病毒性肝病所致肝硬化患者以及肝细胞癌合并肝硬化患者血清中sLFA-3浓度显著升高。sLFA-3和sICAM-1水平升高可能反映了肝硬化中的全身性炎症，且sICAM-1和sLFA-3通过干扰细胞间相互作用可能限制炎症程度。
